Cargando…

Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study

INTRODUCTION: Recurrence rate following radical therapy for lung cancer remains high, potentially reflecting occult metastatic disease, and better staging tools are required. Minimal pleural effusion (mini-PE) is associated with particularly high recurrence risk and is defined as an ipsilateral pleu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Jenny, Tsim, Selina, Kelly, Caroline, Alexander, Laura, Shad, Shumaila, Neilly, Mark, Tate, Matthew, Zahra, Baryab, Saleh, Merna, Cowell, Gordon, Banks, Elspeth, Grundy, Seamus, Corcoran, John, Downer, Nicola, Stanton, Andrew, Evison, Matthew, Rahman, Najib M, Maskell, Nick, Blyth, Kevin G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668291/
https://www.ncbi.nlm.nih.gov/pubmed/37996118
http://dx.doi.org/10.1136/bmjresp-2023-001771
_version_ 1785149103742648320
author Ferguson, Jenny
Tsim, Selina
Kelly, Caroline
Alexander, Laura
Shad, Shumaila
Neilly, Mark
Tate, Matthew
Zahra, Baryab
Saleh, Merna
Cowell, Gordon
Banks, Elspeth
Grundy, Seamus
Corcoran, John
Downer, Nicola
Stanton, Andrew
Evison, Matthew
Rahman, Najib M
Maskell, Nick
Blyth, Kevin G
author_facet Ferguson, Jenny
Tsim, Selina
Kelly, Caroline
Alexander, Laura
Shad, Shumaila
Neilly, Mark
Tate, Matthew
Zahra, Baryab
Saleh, Merna
Cowell, Gordon
Banks, Elspeth
Grundy, Seamus
Corcoran, John
Downer, Nicola
Stanton, Andrew
Evison, Matthew
Rahman, Najib M
Maskell, Nick
Blyth, Kevin G
author_sort Ferguson, Jenny
collection PubMed
description INTRODUCTION: Recurrence rate following radical therapy for lung cancer remains high, potentially reflecting occult metastatic disease, and better staging tools are required. Minimal pleural effusion (mini-PE) is associated with particularly high recurrence risk and is defined as an ipsilateral pleural collection (<1/3 hemithorax on chest radiograph), which is either too small to safely aspirate fluid for cytology using a needle, or from which fluid cytology is negative. Thoracoscopy (local anaesthetic thoracoscopy (LAT) or video-assisted thoracoscopic surgery (VATS)) is the gold-standard diagnostic test for pleural malignancy in patients with larger symptomatic effusions. Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY) will prospectively evaluate thoracoscopic staging in lung cancer associated-mini-PE for the first time. METHODS AND ANALYSIS: STRATIFY is a prospective multicentre observational study. Recruitment opened in January 2020. The primary objective is to determine the prevalence of detectable occult pleural metastases (OPM). Secondary objectives include assessment of technical feasibility and safety, and the impact of thoracoscopy results on treatment plans, overall survival and recurrence free survival. Inclusion criteria are (1) suspected/confirmed stages I–III lung cancer, (2) mini-PE, (3) Performance Status 0–2 (4), radical treatment feasible if OPM excluded, (5) ≥16 years old and (6) informed consent. Exclusion criteria are any metastatic disease or contraindication to the chosen thoracoscopy method (LAT/VATS). All patients have LAT or VATS within 7 (±5) days of registration, with results returned to lung cancer teams for treatment planning. Following an interim analysis, the sample size was reduced from 96 to 50, based on a lower-than-expected OPM rate. An MRI substudy was removed in November 2022 due to pandemic-related site setup/recruitment delays. These also necessitated a no-cost recruitment extension until October 2023. ETHICS AND DISSEMINATION: Protocol approved by the West of Scotland Research Ethics Committee (Ref: 19/WS/0093). Results will be published in peer-reviewed journals and presented at international meetings. TRIAL REGISTRATION NUMBER: ISRCTN13584097.
format Online
Article
Text
id pubmed-10668291
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-106682912023-11-23 Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study Ferguson, Jenny Tsim, Selina Kelly, Caroline Alexander, Laura Shad, Shumaila Neilly, Mark Tate, Matthew Zahra, Baryab Saleh, Merna Cowell, Gordon Banks, Elspeth Grundy, Seamus Corcoran, John Downer, Nicola Stanton, Andrew Evison, Matthew Rahman, Najib M Maskell, Nick Blyth, Kevin G BMJ Open Respir Res Lung Cancer INTRODUCTION: Recurrence rate following radical therapy for lung cancer remains high, potentially reflecting occult metastatic disease, and better staging tools are required. Minimal pleural effusion (mini-PE) is associated with particularly high recurrence risk and is defined as an ipsilateral pleural collection (<1/3 hemithorax on chest radiograph), which is either too small to safely aspirate fluid for cytology using a needle, or from which fluid cytology is negative. Thoracoscopy (local anaesthetic thoracoscopy (LAT) or video-assisted thoracoscopic surgery (VATS)) is the gold-standard diagnostic test for pleural malignancy in patients with larger symptomatic effusions. Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY) will prospectively evaluate thoracoscopic staging in lung cancer associated-mini-PE for the first time. METHODS AND ANALYSIS: STRATIFY is a prospective multicentre observational study. Recruitment opened in January 2020. The primary objective is to determine the prevalence of detectable occult pleural metastases (OPM). Secondary objectives include assessment of technical feasibility and safety, and the impact of thoracoscopy results on treatment plans, overall survival and recurrence free survival. Inclusion criteria are (1) suspected/confirmed stages I–III lung cancer, (2) mini-PE, (3) Performance Status 0–2 (4), radical treatment feasible if OPM excluded, (5) ≥16 years old and (6) informed consent. Exclusion criteria are any metastatic disease or contraindication to the chosen thoracoscopy method (LAT/VATS). All patients have LAT or VATS within 7 (±5) days of registration, with results returned to lung cancer teams for treatment planning. Following an interim analysis, the sample size was reduced from 96 to 50, based on a lower-than-expected OPM rate. An MRI substudy was removed in November 2022 due to pandemic-related site setup/recruitment delays. These also necessitated a no-cost recruitment extension until October 2023. ETHICS AND DISSEMINATION: Protocol approved by the West of Scotland Research Ethics Committee (Ref: 19/WS/0093). Results will be published in peer-reviewed journals and presented at international meetings. TRIAL REGISTRATION NUMBER: ISRCTN13584097. BMJ Publishing Group 2023-11-23 /pmc/articles/PMC10668291/ /pubmed/37996118 http://dx.doi.org/10.1136/bmjresp-2023-001771 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Lung Cancer
Ferguson, Jenny
Tsim, Selina
Kelly, Caroline
Alexander, Laura
Shad, Shumaila
Neilly, Mark
Tate, Matthew
Zahra, Baryab
Saleh, Merna
Cowell, Gordon
Banks, Elspeth
Grundy, Seamus
Corcoran, John
Downer, Nicola
Stanton, Andrew
Evison, Matthew
Rahman, Najib M
Maskell, Nick
Blyth, Kevin G
Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title_full Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title_fullStr Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title_full_unstemmed Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title_short Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
title_sort staging by thoracoscopy in potentially radically treatable lung cancer associated with minimal pleural effusion (stratify): protocol of a prospective, multicentre, observational study
topic Lung Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668291/
https://www.ncbi.nlm.nih.gov/pubmed/37996118
http://dx.doi.org/10.1136/bmjresp-2023-001771
work_keys_str_mv AT fergusonjenny stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT tsimselina stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT kellycaroline stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT alexanderlaura stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT shadshumaila stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT neillymark stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT tatematthew stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT zahrabaryab stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT salehmerna stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT cowellgordon stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT bankselspeth stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT grundyseamus stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT corcoranjohn stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT downernicola stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT stantonandrew stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT evisonmatthew stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT rahmannajibm stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT maskellnick stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy
AT blythkeving stagingbythoracoscopyinpotentiallyradicallytreatablelungcancerassociatedwithminimalpleuraleffusionstratifyprotocolofaprospectivemulticentreobservationalstudy